CRISPR Therapeutics says its new gene editing tool is ‘a significant advance’ over prime editing. Prime Medicine disagreesnews2025-10-21T11:00:14+00:00October 21st, 2025|Endpoints News|
Galapagos to exit cell therapy, with loss of 365 jobs and global sites to shutternews2025-10-21T10:56:09+00:00October 21st, 2025|Endpoints News|
Pregene lands up to $1.52B deal with Kite for in vivo therapiesnews2025-10-16T19:25:26+00:00October 16th, 2025|Endpoints News|
Exclusive: Lipid nanoparticle startup emerges with $31M from Khosla for in vivo cell therapiesnews2025-10-15T13:00:10+00:00October 15th, 2025|Endpoints News|
A gene therapy pioneer reckons with the reality for ultra-rare diseasesnews2025-10-14T15:33:45+00:00October 14th, 2025|Endpoints News|
Q&A: Nobel winner Fred Ramsdell on basic research in biotech, and the future of cell therapynews2025-10-14T14:41:49+00:00October 14th, 2025|Endpoints News|
Novo Nordisk quits cell therapy as restructure continuesnews2025-10-13T11:05:02+00:00October 13th, 2025|Endpoints News|
Regeneron heads to FDA to seek approval for hearing loss gene therapynews2025-10-13T09:02:48+00:00October 13th, 2025|Endpoints News|
New study suggests patients with anti-AAV antibodies may still receive gene therapynews2025-10-10T18:47:55+00:00October 10th, 2025|Endpoints News|
Cabaletta Bio says small number of autoimmune patients responded to its CAR-T without toxic preconditioningnews2025-10-10T14:35:34+00:00October 10th, 2025|Endpoints News|
